Siu Alan, Rangarajan Sanjeet, Karsy Michael, Farrell Christopher J, Nyquist Gurston, Rosen Marc, Evans James J
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
Department of Otolaryngology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
J Neurol Surg B Skull Base. 2021 Sep 10;83(Suppl 2):e591-e597. doi: 10.1055/s-0041-1735636. eCollection 2022 Jun.
Pituitary apoplexy is an uncommon clinical condition that can require urgent surgical intervention, but the factors resulting in recurrent apoplexy remain unclear. The purpose of this study is to determine the risks of a recurrent apoplexy and better understand the goals of surgical treatment. A retrospective chart review was performed for all consecutive patients diagnosed and surgically treated for pituitary apoplexy from 2004 to 2021. Univariate analysis was performed to identify risk factors associated with recurrent apoplexy. A total of 115 patients were diagnosed with pituitary apoplexy with 11 patients showing recurrent apoplexy. This occurred at a rate of 2.2 cases per 100 patient-years of follow-up. There were no major differences in demographic factors, such as hypertension or anticoagulation use. There were no differences in tumor locations, cavernous sinus invasion, or tumor volumes (6.84 ± 4.61 vs. 9.15 ± 8.45 cm, = 0.5). Patients with recurrent apoplexy were less likely to present with headache (27.3%) or ophthalmoplegia (9.1%). Recurrent apoplexy was associated with prior radiation (0.0 vs. 27.3%, = 0.0001) and prior subtotal resection (10.6 vs. 90.9%, = 0.0001) compared with first time apoplexy. The mean time to recurrent apoplexy was 48.3 ± 76.9 months and no differences in overall follow-up were seen in this group. Recurrent pituitary apoplexy represents a rare event with limited understanding of pathophysiology. Prior STR and radiation treatment are associated with an increased risk. The relatively long time from the first apoplectic event to a recurrence suggests long-term patient follow-up is necessary.
垂体卒中是一种罕见的临床病症,可能需要紧急手术干预,但导致复发性卒中的因素仍不清楚。本研究的目的是确定复发性卒中的风险,并更好地理解手术治疗的目标。
对2004年至2021年期间所有连续诊断并接受垂体卒中手术治疗的患者进行了回顾性病历审查。进行单因素分析以确定与复发性卒中相关的危险因素。
共有115例患者被诊断为垂体卒中,其中11例出现复发性卒中。发生率为每100患者年随访2.2例。在人口统计学因素方面,如高血压或抗凝药物使用,没有显著差异。肿瘤位置、海绵窦侵犯或肿瘤体积(6.84±4.61 vs. 9.15±8.45 cm,P = 0.5)也没有差异。复发性卒中患者出现头痛(27.3%)或眼肌麻痹(9.1%)的可能性较小。与首次卒中相比,复发性卒中与既往放疗(0.0% vs. 27.3%,P = 0.0001)和既往次全切除(10.6% vs. 90.9%,P = 0.0001)相关。复发性卒中的平均时间为48.3±76.9个月,该组在总体随访中未见差异。
复发性垂体卒中是一种罕见事件,对其病理生理学的了解有限。既往次全切除和放疗与风险增加相关。从首次卒中事件到复发的时间相对较长,这表明有必要对患者进行长期随访。